3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Neoplasms
10
Carcinoma, Non-Small-Cell Lung
7
Ovarian Neoplasms
6
Carcinoma, Transitional Cell
6
Squamous Cell Carcinoma of Head and Neck
5
Neoplasm Metastasis
5
Carcinoma, Renal Cell
5
Breast Neoplasms
4
Triple Negative Breast Neoplasms
3
Recurrence
3
Melanoma
3
Colorectal Neoplasms
3
Urinary Bladder Neoplasms
2
Sarcoma
2
Lymphoma, Follicular
2
Lymphoma
2
Central Nervous System Neoplasms
2
Uveal Melanoma
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Solid Tumors
1
Skin Neoplasms
1
Sezary Syndrome
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Peritoneal Neoplasms
1
Pancreatic Neoplasms
1
Mycosis Fungoides
1
Metastatic Urothelial Cell Cancer
1
Metastatic Solid Tumors
1
Interventions
pembrolizumab
11
Nivolumab
7
Sunitinib
6
Cyclophosphamide
6
aldesleukin
5
Sorafenib
5
Everolimus
5
temsirolimus
4
belzutifan
4
atezolizumab
4
Ipilimumab
4
fludarabine
3
cabozantinib
3
Interferon-alpha
3
Gene Expression Profiling
3
Fluorouracil
3
Docetaxel
3
Cetuximab
3
Busulfan
3
valspodar
2
sargramostim
2
perifosine
2
pazopanib
2
ixabepilone
2
entinostat
2
ciforadenant
2
belinostat
2
Thiotepa
2
Temozolomide
2
Sirolimus
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Kidney Neoplasms
×
avelumab
×
Clear all
NCT02493751
2022-02-18
JAVELIN Renal 100
Pfizer
Phase 1
Completed
55 enrolled
27 charts